Relation of natriuretic peptides and midregional proadrenomedullin to cardiac chamber volumes by computed tomography in patients without heart failure: From the ROMICAT trial

Clinical Chemistry

Volumn 56, Issue 4, 2010, Pages 651-660

  Truong, Quynh A ^a   Siegel, Emily ^a   Karakas, Mahir ^b   Januzzi Jr , James L ^a   Bamberg, Fabian ^a   Mahabadi, Amir A ^a   Dasdemir, Selcuk ^b   Brady, Thomas J ^a   Bergmann, Andreas ^c   Kunde, Jan ^c   Nagurney, John T ^a   Hoffmann, Udo ^a   Koenig, Wolfgang ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ULM   (Germany)

^c BRAHMS CO ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; MID REGIONAL PRO AMINO TERMINAL A TYPE NATRIURETIC PEPTIDE; MIDREGIONAL PROADRENOMEDULLIN; NATRIURETIC FACTOR; PROADRENOMEDULLIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEART ATRIUM HYPERTROPHY; HEART FAILURE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE VOLUME; HEART VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK ASSESSMENT; THORAX PAIN;

ADRENOMEDULLIN; ATRIAL FUNCTION, LEFT; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PROTEIN PRECURSORS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; VENTRICULAR FUNCTION, LEFT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77950570484     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.138586     Document Type: Article

References (39)

1. Mohammed AA, Januzzi JL Jr. Natriuretic peptides in the diagnosis and management of acute heart failure. Heart Fail Clin 2009;5:489-500.
2. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007;13:42-49 (Pubitemid 46343794)
3. Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2009;54:357-364
4. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993;132:1961-1970 (Pubitemid 23133241)
5. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203. (Pubitemid 24203680)
6. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, Pedersen F. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-751 (Pubitemid 36760633)
7. Bay M, Kirk V, Parner J, Hassager C, Nielsen H, Krogsgaard K, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003;89:150-154 (Pubitemid 36115095)
8. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004;43:55-60. (Pubitemid 38045916)
9. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett JC Jr. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993;341:1105-1109 (Pubitemid 23125852)
10. Gegenhuber A, Struck J, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 2006;52:827-831 (Pubitemid 43673260)
11. Potocki M, Breidthardt T, Reichlin T, Hartwiger S, Morgenthaler NG, Bergmann A, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med 2010;267:119-129
12. Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, et al. Plasma N-terminal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2008;51:1857- 1864.
13. von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1973-1980 (Pubitemid 350046336)
14. Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG, et al. Comparison of mid-regional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 2009;53:1783-1790
15. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-560 (Pubitemid 23227359)
16. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 1994;338:6-10. (Pubitemid 24047772)
17. Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 1994;201:1160-1166 (Pubitemid 24234212)
18. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21:138-167
19. Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei CM, McKinley LJ, Burnett JC Jr. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 1996;97:2370-2376 (Pubitemid 26165726)
20. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004;25:1369-1372 (Pubitemid 39180069)
21. Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007;49:1525-1532 (Pubitemid 46517963)
22. Mahabadi AA, Samy B, Seneviratne SK, Toepker MH, Bamberg F, Hoffmann U, Truong QA. Quantitative assessment of left atrial volume by electrocardiographic-gated contrast-enhanced multidetector computed tomography. J Cardiovasc Comput Tomogr 2009;3:80-87
23. Stolzmann P, Scheffel H, Leschka S, Schertler T, Frauenfelder T, Kaufmann PA, et al. Reference values for quantitative left ventricular and left atrial measurements in cardiac computed tomography. Eur Radiol 2008;18:1625-1634
24. Hoffmann U, Bamberg F, Chae CU, Nichols JH, Rogers IS, Seneviratne SK, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction Using Computer Assisted Tomography) trial. J Am Coll Cardiol 2009;53:1642-1650
25. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-236 (Pubitemid 38125732)
26. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823-1829 (Pubitemid 41368172)
27. DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:865-871
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease study group. Ann Intern Med 1999;130:461-470 (Pubitemid 29135798)
29. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639 (Pubitemid 44969122)
30. Rehman S, Lloyd-Jones DM, Martinez-Rumayor A, Januzzi JL. Inflammatory markers, amino-terminal pro-brain natriuretic peptide, and mortality risk in dyspneic patients. Am J Clin Pathol 2008;130:305-311
31. Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL Jr. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta 2008;392:41-45
32. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-1224 (Pubitemid 44345127)
33. Elmas E, Brueckmann M, Lang S, Kalsch T, Haghi D, Sueselbeck T, et al. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease. Int J Cardiol 2008;128:244-249 (Pubitemid 352033584)
34. Moller JE, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS, et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 2003;107:2207-2212 (Pubitemid 36547214)
35. Li D, Wen JF, Jin JY, Quan HX, Cho KW. Cardiac mast cells regulate myocyte ANP release via histamine H2 receptor in beating rabbit atria. Regul Pept 2009;155:33-38
36. Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, Okutani Y. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ J 2008;72:1777-1786
37. Behnes M, Papassotiriou J, Walter T, Fiedler E, Sauer T, Lang S, et al. Long-term prognostic value of mid-regional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction. Clin Chem Lab Med 2008;46:204-211
38. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49-57.
39. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage laboratory medicine practice guidelines: analytical issues for biomarkers of heart failure. Clin Biochem 2008;41:222-226 (Pubitemid 351240895)